AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14512676 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGhaler (beclomethasone dipropionate 1,000 microg/day)
Number of subjects: 171
Study 14512676 — intervention group
Group type: COMPARATOR
Intervention: MDI (beclomethasone dipropionate 1,000 microg/day)
Number of subjects: 171
Study 14512676 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGhaler
Number of subjects: 171
Study 14512676 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 171
Study 11826695 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 2% xylocaine with 1:80,000 epinephrine
Number of subjects: 0
Study 11826695 — intervention group
Group type: COMPARATOR
Intervention: Non-injected inferior turbinate
Number of subjects: 0
Study 9893655 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy (FEC: 5‐fluorouracil 600 mg/m2, epidoxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2)
Number of subjects: 70
Study 9893655 — intervention group
Group type: EXPERIMENTAL
Intervention: High [3H]‐dT‐LI
Number of subjects: 70
Study 9893655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low [3H]‐dT‐LI
Number of subjects: 70
Study 9893655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological complete response after induction treatment
Number of subjects: 70
Study 9893655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low [3H]‐dT‐LI after primary chemotherapy
Number of subjects: 70
Study 9893655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bcl-2 expression before primary chemotherapy
Number of subjects: 70
Study 9893655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bcl-2 expression after primary chemotherapy
Number of subjects: 70
Study 7841754 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiyaning (FYN)
Number of subjects: 40
Study 7841754 — intervention group
Group type: COMPARATOR
Intervention: Ligustrazine (LT)
Number of subjects: 40
Study 3277083 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.25 to 0.5 mg/d)
Number of subjects: 12
Study 30946274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Group (LIG)
Number of subjects: 39
Study 30946274 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Group (MIG)
Number of subjects: 39
Study 30946274 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Group (HIG)
Number of subjects: 39
Study 30946274 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 39
Study 30946274 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of LIG to HIG
Number of subjects: 39
Study 30946274 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of LIG and MIG to HIG
Number of subjects: 39
Study 30946274 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining effects
Number of subjects: 39
Study 30587469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough (EMA) granules
Number of subjects: 150
Study 30587469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 27253184 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted early intervention program involving home visits from pregnancy onwards
Number of subjects: 164
Study 27253184 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 164
Study 25796512 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI categories (overweight and obese subclasses)
Number of subjects: 1030
Study 25796512 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM diagnosis
Number of subjects: 1030
Study 25796512 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (independent of GDM)
Number of subjects: 1030
Study 23097067 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (target dose 40 mg three times per day)
Number of subjects: 210
Study 23097067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 24482850 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiting service
Number of subjects: 216
Study 24482850 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 216
Study 18580411 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast bathing (CB)
Number of subjects: 26
Study 18580411 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garments (CG)
Number of subjects: 26
Study 18580411 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 26
Study 16507180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position with operative side down (Group 1)
Number of subjects: 80
Study 16507180 — intervention group
Group type: COMPARATOR
Intervention: Sitting position then turned to lateral side (Group 2)
Number of subjects: 80
Study 12741874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (slow self-paced jogging)
Number of subjects: 14
Study 12741874 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (standing still)
Number of subjects: 14
Study 12741874 — intervention group
Group type: EXPERIMENTAL
Intervention: Long line version
Number of subjects: 14
Study 12741874 — intervention group
Group type: COMPARATOR
Intervention: Short line version
Number of subjects: 14
Study 10757621 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (50 pmol/kg x h)
Number of subjects: 20
Study 10757621 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20
Study 8818093 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea (150 ml)
Number of subjects: 40
Study 8818093 — intervention group
Group type: COMPARATOR
Intervention: Apple juice (150 ml)
Number of subjects: 40
Study 1446762 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (50 i.u./ml) and adrenaline (1:200,000)
Number of subjects: 91
Study 1446762 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase alone
Number of subjects: 91
Study 1446762 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline alone
Number of subjects: 91
Study 1446762 — intervention group
Group type: COMPARATOR
Intervention: Neither hyaluronidase nor adrenaline
Number of subjects: 91
Study 31086379 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention 'Clean Hands, Happy Life' including HH products, reminders, training programs, and a kick-off event.
Number of subjects: 176
Study 31086379 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention 'Clean Hands, Happy Life'.
Number of subjects: 176
Study 27364689 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 120
Study 27364689 — intervention group
Group type: COMPARATOR
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 120
Study 27364689 — intervention group
Group type: COMPARATOR
Intervention: Swaddling
Number of subjects: 120
Study 25881813 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine methods plus dietary sweet potato consumption (200 g/d from admission to discharge)
Number of subjects: 120
Study 25881813 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing methods
Number of subjects: 120
Study 24902735 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 52
Study 24902735 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 52
Study 24902735 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study 21978572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 3117
Study 21978572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 3117
Study 21978572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3117
Study 20958888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 156
Study 20958888 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 156
Study 20958888 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 156
Study 17383174 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin E (800 mg)
Number of subjects: 16
Study 17383174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15665146 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with histories of syncope
Number of subjects: 14
Study 15665146 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study 12413315 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 22
Study 12413315 — intervention group
Group type: COMPARATOR
Intervention: Conventional repair
Number of subjects: 22
Study 10607223 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 24
Study 7852539 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex (150 mg) three times daily for 6 weeks
Number of subjects: 57
Study 7852539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2182170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 43
Study 2182170 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 43
Study 2182170 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 43
Study 7005122 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 0
Study 7005122 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg atenolol
Number of subjects: 0
Study 7005122 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 28315910 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (300μg orally for 10 days)
Number of subjects: 16
Study 28315910 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 16
Study 26712981 — intervention group
Group type: EXPERIMENTAL
Intervention: IV clonidine 4 µg/kg
Number of subjects: 90
Study 26712981 — intervention group
Group type: EXPERIMENTAL
Intervention: IV clonidine 5 µg/kg
Number of subjects: 90
Study 26712981 — intervention group
Group type: EXPERIMENTAL
Intervention: IV clonidine 3 µg/kg
Number of subjects: 90
Study 23736524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration of the palmar surface of the hand
Number of subjects: 12
Study 23736524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration of the forearm applied over the flexor muscles
Number of subjects: 12
Study 23736524 — intervention group
Group type: COMPARATOR
Intervention: No vibration
Number of subjects: 12
Study 22338149 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rituximab weekly for 4 weeks (group A)
Number of subjects: 51
Study 22338149 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg/m2 rituximab single dose (group B)
Number of subjects: 51
Study 19662727 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper canal preparation and single cone obturation with matching gutta‐percha point
Number of subjects: 42
Study 19662727 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper preparation plus thermoplastic obturation (Thermafil)
Number of subjects: 42
Study 19662727 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile .06 taper and matching master cone with lateral condensation
Number of subjects: 42
Study 17931541 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprinted medication labels
Number of subjects: 0
Study 17931541 — intervention group
Group type: COMPARATOR
Intervention: Blank medication labels
Number of subjects: 0
Study 15355745 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting cytokines (IL-6, IL-12, IL-15, IL-18)
Number of subjects: 0
Study 15355745 — intervention group
Group type: COMPARATOR
Intervention: Tumor necrosis factor blocking agents
Number of subjects: 0
Study 11317091 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for physicians emphasizing avoidance of NSAIDs, including face-to-face visits and reminder placements in patient charts.
Number of subjects: 1566
Study 11317091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 1566
Study 9121953 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated Atrial Contraction (AC) during exercise in VVIR mode
Number of subjects: 12
Study 9121953 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated Atrial Contraction (AC) during exercise in VVI mode
Number of subjects: 12
Study 9121953 — intervention group
Group type: COMPARATOR
Intervention: Chronic Atrial Fibrillation (AF) during exercise in VVIR mode
Number of subjects: 12
Study 9121953 — intervention group
Group type: COMPARATOR
Intervention: Chronic Atrial Fibrillation (AF) during exercise in VVI mode
Number of subjects: 12
Study 9121953 — intervention group
Group type: COMPARATOR
Intervention: Resting levels in Chronic Atrial Fibrillation (AF)
Number of subjects: 12
Study 9121953 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting levels in Coordinated Atrial Contraction (AC)
Number of subjects: 12
Study 8033771 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 60
Study 8033771 — intervention group
Group type: COMPARATOR
Intervention: Hydroflumethiazide
Number of subjects: 60
Study 3322537 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hydroxybenzo[b]thiophene-2-sulfonamide, 2% suspension, administered twice daily for 1 week to one eye
Number of subjects: 20
Study 3322537 — intervention group
Group type: COMPARATOR
Intervention: Placebo drop, administered twice daily for 1 week to one eye
Number of subjects: 20
Study 30087002 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 96
Study 30087002 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 96
Study 30087002 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Number of subjects: 96
Study 28635980 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality educational intervention (video, PowerPoint slides, medical illustrations)
Number of subjects: 8
Study 28635980 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality educational intervention
Number of subjects: 8
Study 28635980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 25729161 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic electrical stimulation during expiration (PESE)
Number of subjects: 24
Study 25729161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23307806 — intervention group
Group type: EXPERIMENTAL
Intervention: Flinders Program plus usual care
Number of subjects: 77
Study 23307806 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 77
Study 22014807 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 80 mg by mouth daily
Number of subjects: 847
Study 22014807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study 19151449 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin low dose (3 times 15 mg/day)
Number of subjects: 75
Study 19151449 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin moderate dose (3 times 30 mg/day)
Number of subjects: 75
Study 19151449 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin high dose (3 times 60 mg/day)
Number of subjects: 75
Study 19151449 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (all doses)
Number of subjects: 75
Study 19151449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 16531903 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg.kg(‐1) bw pseudoephedrine
Number of subjects: 7
Study 16531903 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg.kg(‐1) bw maltodextrins (placebo)
Number of subjects: 7
Study 14625607 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection (PEI)
Number of subjects: 27
Study 14625607 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous hydrochloric acid injection (PHI)
Number of subjects: 27
Study 14625607 — intervention group
Group type: COMPARATOR
Intervention: Needle aspiration only
Number of subjects: 27
Study 11084175 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regimen of oral conjugated equine estrogens (CEE), 0.625 mg/day, combined with medroxyprogesterone acetate (MPA), 5.0 mg/day
Number of subjects: 1724
Study 11084175 — intervention group
Group type: COMPARATOR
Intervention: Continuous regimen of oral conjugated equine estrogens (CEE), 0.625 mg/day, combined with medroxyprogesterone acetate (MPA), 2.5 mg/day
Number of subjects: 1724
Study 9065552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepidermal nerve fiber (IENF) density measurement in patients with painful sensory neuropathies
Number of subjects: 0
Study 9065552 — intervention group
Group type: COMPARATOR
Intervention: Intraepidermal nerve fiber (IENF) density measurement in control subjects
Number of subjects: 0
Study 9065552 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IENF density with clinical estimates of neuropathy severity
Number of subjects: 0
Study 9065552 — intervention group
Group type: EXPERIMENTAL
Intervention: IENF density measurement at the calf
Number of subjects: 0
Study 8445814 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters)
Number of subjects: 803
Study 8445814 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction (reducers)
Number of subjects: 803
Study 8445814 — intervention group
Group type: COMPARATOR
Intervention: No change in smoking behavior (no changers)
Number of subjects: 803
Study 8445814 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction
Number of subjects: 803
Study 3554991 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 19
Study 3554991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31047790 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 99
Study 31047790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 99
Study 31047790 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 99
Study 31047790 — intervention group
Group type: EXPERIMENTAL
Intervention: PT followed by an increased dose of PT (PT-PT)
Number of subjects: 99
Study 31047790 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT followed by an increased dose of CBT (CBT-CBT)
Number of subjects: 99
Study 31047790 — intervention group
Group type: EXPERIMENTAL
Intervention: PT followed by CBT (PT-CBT)
Number of subjects: 99
Study 31047790 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT followed by PT (CBT-PT)
Number of subjects: 99
Study 28643374 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2510924 (20 mg once daily)
Number of subjects: 0
Study 28643374 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2510924 (subcutaneous administration)
Number of subjects: 0
Study 28643374 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2510924
Number of subjects: 0
Study 26407017 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 G needle
Number of subjects: 200
Study 26407017 — intervention group
Group type: COMPARATOR
Intervention: 25 G needle
Number of subjects: 200
Study 26407017 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety prior to arterial puncture
Number of subjects: 200
Study 26407017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain experienced during arterial puncture
Number of subjects: 200
Study 22951158 — intervention group
Group type: EXPERIMENTAL
Intervention: blood‐based crisp bread (35 mg of iron, 27 mg heme Fe)
Number of subjects: 77
Study 22951158 — intervention group
Group type: EXPERIMENTAL
Intervention: iron supplementation (35 mg of non‐heme iron/day)
Number of subjects: 77
Study 22951158 — intervention group
Group type: EXPERIMENTAL
Intervention: iron supplementation (60 mg of non‐heme iron/day)
Number of subjects: 77
Study 22951158 — intervention group
Group type: COMPARATOR
Intervention: control (iron‐free tablets)
Number of subjects: 77
Study 21272186 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + pioglitazone 45 mg (n = 12)
Number of subjects: 25
Study 21272186 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy alone (n = 13)
Number of subjects: 25
Study 19039237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GH for 2 years (0.033/0.033 mg/kg/day, n = 51)
Number of subjects: 151
Study 19039237 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH for 1 year and then no treatment for 1 year (0.100/0 mg/kg/day, n = 51)
Number of subjects: 151
Study 19039237 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dose GH for 1 year (0/0.067 mg/kg/day, n = 47)
Number of subjects: 151
Study 19039237 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated for 1 year)
Number of subjects: 151
Study 19039237 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of high-dose and low-dose GH after 2 years
Number of subjects: 151
Study 17697905 — intervention group
Group type: EXPERIMENTAL
Intervention: SKI306X 200 mg TID
Number of subjects: 183
Study 17697905 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg BID
Number of subjects: 183
Study 15179169 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training (CONT)
Number of subjects: 20
Study 15179169 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (INT)
Number of subjects: 20
Study 15179169 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 11986726 — intervention group
Group type: EXPERIMENTAL
Intervention: New inactivated HAV vaccine (1000 units)
Number of subjects: 31
Study 11986726 — intervention group
Group type: COMPARATOR
Intervention: Havrix (720 ELISA units)
Number of subjects: 31
Study 9803693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program delivered on a weekend for groups of 4 couples
Number of subjects: 67
Study 9803693 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 67
Study 9803693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program
Number of subjects: 67
Study 7702198 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg/day)
Number of subjects: 53
Study 7702198 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg/day)
Number of subjects: 53
Study 2644795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone, 2 mg/kg over 10 minutes
Number of subjects: 15